CJC-1295

CJC-1295 Peptide: Complete Guide for Medical Professionals

Available in both DAC and no-DAC versions, CJC-1295 is commonly discussed in clinical and research settings focused on growth hormone modulation. Its unique characteristics have contributed to growing interest among medical professionals exploring peptide therapies and structured endocrine support strategies for carefully selected patients within individualized treatment approaches.  Within the broader peptides category, CJC-1295 is commonly discussed in research settings focused on growth hormone modulation. This guide explores the mechanism of action, clinical applications, dosing considerations, safety profile, and protocol strategies for licensed medical professionals. Note: CJC-1295 is an investigational compound not approved by the FDA for any clinical indication. The following summary reflects findings from preclinical and early-phase human research. Nothing in this guide constitutes clinical guidance or a recommendation for use in patients.

What Is CJC 1295?

CJC-1295 is a synthetic growth hormone-releasing hormone (GHRH) analogue that has been investigated for its ability to stimulate endogenous growth hormone production. In research settings, it has been studied for its effects on receptors in the anterior pituitary, where it promotes GH release through physiologic mechanisms rather than directly supplying recombinant GH. Its two formulations, with DAC and without DAC, differ primarily in duration of action and dosing frequency. This peptide exists in two primary forms:

• CJC-1295 with DAC (Drug Affinity Complex)
• CJC-1295 no-DAC (MOD GRF 1-29)

The distinction between these variants is pharmacologically significant. The DAC-modified version is engineered to bind covalently to circulating albumin, extending its half-life to approximately 6–8 days. This results in sustained GH stimulation in research subjects and allows for infrequent dosing schedules. In contrast, the no-DAC version has a short half-life of around 30 minutes, closely resembling the natural pulsatile secretion pattern of endogenous GHRH. Because of its pharmacologic flexibility, the CJC 1295 peptide has become a notable subject in investigational peptide research focused on GH modulation, metabolic function, and regenerative biology.

CJC-1295 Mechanism of Action

CJC-1295 exerts its effects by selectively binding to GHRH receptors located on somatotroph cells in the anterior pituitary. This receptor activation initiates intracellular signaling pathways that lead to the synthesis and release of growth hormone. Once released, GH enters systemic circulation and stimulates hepatic production of insulin-like growth factor 1 (IGF-1), which mediates many of the anabolic and metabolic effects associated with GH activity.

Mechanistic Breakdown

• Receptor-Level Activation: CJC-1295 mimics endogenous GHRH, binds to pituitary receptors, and triggers GH release.
• Pulsatile GH Secretion: Particularly with the no-DAC variant, GH is released in pulses that align with physiologic rhythms, reducing the risk of receptor desensitization.
• IGF-1 Elevation: Research has associated sustained increases in IGF-1 levels with downstream effects on tissue growth, repair, and metabolic regulation.
• DAC Modification: The Drug Affinity Complex prolongs peptide activity by binding to albumin, allowing continuous stimulation without frequent injections.
• Synergistic Potential: In research settings, CJC-1295 has been studied alongside GHRPs such as Ipamorelin, which activate ghrelin receptors to complement CJC-1295's action at the GHRH receptor. Investigators note enhanced GH pulse amplitude and frequency.

Clinical data support these mechanisms. A study by Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006) demonstrated that a single dose of CJC-1295 significantly increased plasma GH and IGF-1 levels for up to several days in healthy adult subjects, particularly with DAC modification.

CJC-1295 Benefits

Preclinical and early-phase human research on CJC 1295 has examined its effects across several physiological domains. These areas represent investigational findings and should not be interpreted as established clinical outcomes or treatment indications.

1. Muscle Growth, Fat Loss, and Recovery

Research has examined CJC-1295's effects on IGF-1-mediated protein synthesis and muscle cell repair. Studies on GH axis stimulation more broadly have associated elevated IGF-1 with nitrogen retention and lipolysis, areas that investigators have explored in the context of body composition research. For investigational protocols focused strictly on isolated fat metabolism, the AOD peptide guide offers a highly relevant alternative profile to consider.

2. Improved Sleep Quality

GH secretion is closely tied to slow-wave (deep) sleep. Research on GHRH analogues has explored whether amplifying GH pulses (particularly when dosed in the evening) may influence sleep architecture. This remains an area of ongoing investigational interest.

3. Enhanced Collagen Synthesis and Tissue Repair

GH and IGF-1 have established roles in fibroblast activity and collagen production in the scientific literature. Researchers have examined whether GHRH analogue-mediated GH stimulation may influence wound healing, joint integrity, and musculoskeletal recovery, though this work remains largely investigational.

4. Anti-Aging and Longevity Support

The age-related decline of GH and IGF-1 has made GHRH analogues a subject of interest in longevity research. Investigators have studied potential associations with collagen metabolism, bone mineral density, and cellular repair, though these applications are not approved indications, and evidence remains preliminary.

CJC-1295 Research Dosing Reference

The following dosing parameters reflect ranges used in published research and investigational settings. They are provided as a scientific reference for licensed professionals and do not constitute dosing instructions or clinical recommendations.

CJC-1295 with DAC

• Research dose: 1-2 mg per week
• Frequency used in studies: Once or twice weekly
• Route: Subcutaneous injection

The DAC-modified version has been studied at extended intervals due to its prolonged half-life, with researchers noting sustained GH stimulation across the dosing window.

CJC-1295 no-DAC (MOD GRF 1-29)

• Research dose: 100–200 mcg per injection
• Frequency used in studies: 2-3 times daily
• Route: Subcutaneous injection

The no-DAC variant has been investigated at more frequent intervals to mimic natural GH pulsatility, allowing researchers to study the effects of physiologic GH release patterns.

Timing Parameters Observed in Research

• Administration in a fasted state has been used in studies to minimize insulin interference with GH release
• Dosing windows studied include pre-sleep (aligning with natural GH peak) and pre-exercise contexts
• Research protocols have typically avoided food intake, particularly carbohydrates, within 60–90 minutes of dosing

Combination with GHRPs

CJC-1295 has been investigated alongside GHRPs such as Ipamorelin. Research designs have explored this combination for its complementary mechanisms: stimulation of the GHRH receptor alongside activation of the ghrelin receptor.

CJC-1295 Investigational Protocol Designs

The following reflects protocol structures observed in research and investigational settings. This is not a treatment protocol and should not be used as one.

Studied Combination: CJC-1295 no-DAC + Ipamorelin

• CJC-1295 no-DAC: 100–200 mcg
• Ipamorelin: 100–200 mcg
• Ratio: 1:1
• Frequency used in studies: 2–3 times daily

This combination has been examined in research settings for its effects on GH release patterns. CJC-1295 stimulates GHRH receptors, while Ipamorelin activates ghrelin receptors, with investigators noting amplified GH pulse amplitude in study subjects.

Cycle Duration

• Active period observed in research: 3–6 months
• Washout period: 1–2 months

Cycling structures have been used in research designs to assess receptor sensitivity and longer-term response patterns.

Research Monitoring Parameters

• Insulin interference: Research protocols have typically controlled for food intake around dosing
• IGF-1 monitoring: Used in studies as a marker of GH axis response
• Individual response tracking: Research designs have incorporated adjustments based on subject tolerance and biomarker data

For alternative or complementary GH-releasing approaches, practitioners may also review the Sermorelin guide and Ipamorelin guide.

CJC-1295 Side Effects

CJC-1295 has been generally well-tolerated in published research at the doses studied. The following adverse effects have been observed or reported in research subjects.

Commonly Reported Effects

• Water Retention: Observed during early stages of study periods, likely associated with fluid balance shifts related to GH activity. Typically transient in research subjects.
• Paresthesia (Tingling or Numbness): Mild sensations in the hands or extremities have been reported, similar to carpal tunnel–like symptoms. These have generally appeared dose-dependent and temporary in study subjects.
• Fatigue or Lethargy: Some research subjects reported initial fatigue that subsided as hormone levels stabilized.
• Injection Site Reactions: Mild redness, irritation, or flushing at the injection site has been reported but is generally short-lived.

Less Common Considerations

• Cortisol and Prolactin Elevation: Higher doses or extended study periods have prompted monitoring of these hormone levels in some research designs.
• Headaches or Mild Edema: Reported less frequently in research subjects, particularly at higher dose escalations.

CJC-1295 vs Sermorelin vs Tesamorelin

Understanding the distinctions among CJC-1295, Sermorelin, and Tesamorelin is relevant when evaluating the GHRH analogue research landscape. All three compounds act on GH-related pathways, but they differ significantly in regulatory status, pharmacokinetics, and evidence base.

Comparison Overview

 

Compound	Half-Life	GH Release Pattern	Primary Research/Approved Use	Regulatory Status
CJC-1295 (DAC)	~6–8 days	Sustained GH stimulation	Investigational — GH axis modulation research	Not FDA-approved for any indication
CJC-1295 (no-DAC)	~30 minutes	Pulsatile, physiologic GH release	Investigational — GH pulse research	Not FDA-approved for any indication
Sermorelin	~10–20 minutes	Pulsatile, physiologic GH release	GH deficiency diagnostic and support protocols	FDA-approved (historically); established clinical use
Tesamorelin	Intermediate duration	Targeted GH/IGF-1 stimulation	HIV-associated lipodystrophy	FDA-approved for specific indication

CJC-1295 vs Sermorelin

Sermorelin is one of the earliest GHRH analogues used in clinical practice and has a well-established safety profile. Its short half-life (~10–20 minutes) closely mirrors endogenous GHRH, resulting in a tightly controlled, pulsatile GH release. It carries a more established regulatory and clinical evidence base than CJC-1295. In contrast, CJC 1295 has been investigated for greater pharmacologic flexibility. The no-DAC version has been studied similarly to Sermorelin but with slightly improved stability, while the DAC-modified form has been examined for prolonged GH stimulation with reduced dosing frequency. Unlike Sermorelin, CJC-1295 does not carry FDA approval and its use remains investigational. For a more detailed comparison of GHRH-related research, see our Sermorelin guide.

CJC-1295 vs Tesamorelin

Tesamorelin is FDA-approved specifically for HIV-associated lipodystrophy and carries the strongest clinical evidence base among these compounds. Its regulatory approval and indication-specific evidence distinguish it clearly from CJC-1295, which holds no equivalent approval status. CJC-1295 has been examined in broader investigational contexts but does not carry the same regulatory endorsement or indication-specific evidence as Tesamorelin. These are distinct compounds at different stages of regulatory development and should not be treated as interchangeable. Researchers interested in indication-specific GH therapies can find comprehensive dosing and efficacy data in the Tesamorelin guide.

Clinical Perspective

When reviewing these compounds, the regulatory status distinction is critical:

• Tesamorelin and Sermorelin have established regulatory pathways and approved or historically approved indications
• CJC-1295 remains investigational with no approved clinical indication
• Research findings should not be extrapolated to patient treatment without appropriate regulatory and ethical frameworks

FAQs — CJC-1295

1. What is the difference between CJC-1295 with DAC and without?

CJC-1295 with DAC has a prolonged half-life of approximately 6–8 days due to albumin binding, which has allowed for less frequent dosing intervals in research settings. The no-DAC version (MOD GRF 1-29) has a short half-life of around 30 minutes and has been studied for its more natural, pulsatile GH release pattern. The pharmacokinetic difference makes them suited to different investigational research designs.

2. Is CJC-1295 the same as Sermorelin?

No, CJC-1295 and Sermorelin are distinct GHRH analogues with different pharmacokinetic profiles and regulatory histories. Sermorelin has a shorter duration of action, a more established clinical evidence base, and a clearer regulatory history, while CJC-1295 remains an investigational compound without approved indications.

3. How long until CJC-1295 shows results?

In published research, changes in GH and IGF-1 levels have been measurable within days of administration. Study subjects have reported subjective changes within the first few weeks, while body composition markers have typically been assessed over multi-month study periods. These are research observations and not guaranteed outcomes.

4. Should CJC-1295 be studied alongside Ipamorelin?

Research designs have frequently combined CJC-1295 with Ipamorelin due to their complementary mechanisms (GHRH receptor stimulation and ghrelin receptor activation respectively), with investigators observing enhanced GH pulse response. This combination has been a common design choice in investigational peptide research.

Final Notes for Practitioners

CJC 1295 remains an active subject in investigational peptide research. Its dual formulation (with and without DAC) provides researchers with pharmacokinetic flexibility for studying GH axis modulation across different research designs. Licensed professionals reviewing this compound should do so within appropriate regulatory and ethical frameworks, recognizing that investigational research findings do not constitute approved clinical guidance.

Citations

1. Mameli C, Guadagni L, Orso M, et al. Epidemiology of growth hormone deficiency in children and adolescents: a systematic review. Endocrine. 2024;85(1):91-98. doi:https://doi.org/10.1007/s12020-024-03778-4
2. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1537
3. Merimee TJ, Fineberg SE. Studies of the growth hormone-releasing factor: physiology and clinical implications. N Engl J Med. 1986;315(7):434-439. doi:10.1056/NEJM198608143150706
4. Alba M, Fintini D, Sagazio A, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(6):E1290-E1294. doi:https://doi.org/10.1152/ajpendo.00201.2006

Disclaimer

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.